JNJ vs PFE
Johnson & Johnson vs Pfizer Inc. · Updated Aug 10, 2026
JNJ — 11 winsPFE — 12 wins
Price Performance
JNJ +50.62%PFE +10.05%
Performance
| JNJ | PFE | |
|---|---|---|
| 1 Month | +1.36% | +11.77% |
| 3 Months | +17.69% | +5.20% |
| 6 Months | +8.54% | -0.75% |
| YTD | +25.87% | +8.49% |
| 1 Year | +51.86% | +11.49% |
| 3 Year | +69.04% | -27.01% |
| 5 Year | +88.26% | -26.61% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JNJ | +26.3% | +43.7% | -9.6% | -12.0% | +3.0% | +9.3% | +7.8% | +14.2% | -7.3% | +20.6% | +14.7% | -1.7% |
| PFE | +7.4% | -6.4% | -10.8% | -43.8% | -9.4% | +60.4% | -0.8% | -9.4% | +19.8% | +9.8% | +1.6% | +3.0% |
Valuation
| JNJ | PFE | |
|---|---|---|
| P/E Ratio | 30.11 | 20.62 |
| Forward P/E | 11.17 | 9.08 |
| PEG Ratio | 2.75 | -3.95 |
| P/S Ratio | 6.48 | 2.41 |
| P/B Ratio | 7.70 | 1.69 |
| EV/EBITDA | 19.63 | 12.85 |
Financials
| JNJ | PFE | |
|---|---|---|
| EPS (TTM) | $8.65 | $1.31 |
| Gross Margin | +71.49% | +67.26% |
| Operating Margin | +26.58% | +27.90% |
| Net Margin | +21.76% | +18.60% |
| ROE | +25.92% | +8.31% |
| ROA | +10.47% | +3.61% |
| Debt/Equity | 0.22 | 0.72 |
Growth
| JNJ | PFE | |
|---|---|---|
| Revenue Growth YoY | +9.91% | +5.37% |
| Revenue Growth QoQ | -2.04% | -17.69% |
| EPS Growth YoY | -52.86% | -9.55% |
| EPS Growth QoQ | +1.90% | +262.07% |
Technical
| JNJ | PFE | |
|---|---|---|
| RSI (14) | 54.17 | 74.45 |
| % From 20-Day SMA | +1.41% | +7.08% |
| % From 50-Day SMA | +4.89% | +7.66% |
| % From 200-Day SMA | +14.05% | +4.40% |
| % From 52-Week High | -5.25% | -6.02% |
| % From 52-Week Low | +52.87% | +14.57% |
Analyst Ratings
JNJ
Buy(22 analysts)
Strong SellHoldStrong Buy
Price Target
$282.08
+9.40% upside
PFE
Hold(15 analysts)
Strong SellHoldStrong Buy
Price Target
$27.33
+2.36% upside
Overview
| JNJ | PFE | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYSE | NYSE |
| Market Cap | $624.74B | $152.40B |
| Shares Outstanding | 2.41B | 5.70B |
| Avg Volume (10D) | 7.60M | 46.73M |
| Dividend Yield | 2.02% | 6.43% |
Frequently Asked Questions
Is JNJ or PFE a better buy right now?
Based on 23 comparable metrics, PFE leads in 12 categories while JNJ leads in 11. PFE has a consensus analyst rating with 15 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, JNJ or PFE?
Over the past year, JNJ returned +51.86% compared to PFE's +11.49%. In the short term (1 month), JNJ returned +1.36% vs PFE's +11.77%.
Is JNJ or PFE more expensive?
JNJ trades at a P/E of 30.11 compared to PFE's 20.62. On a price-to-sales basis, JNJ trades at 6.48x vs PFE's 2.41x. Forward P/E: JNJ at 11.17 vs PFE at 9.08.
Which stock has higher growth, JNJ or PFE?
JNJ's revenue grew +9.91% year-over-year compared to PFE's +5.37%. EPS growth: JNJ at -52.86% vs PFE at -9.55%.
Do JNJ and PFE pay dividends?
JNJ pays a dividend with a yield of 2.02%. PFE pays a dividend with a yield of 6.43%.
Which stock do analysts prefer, JNJ or PFE?
JNJ has 22 analysts with a target price of $282.08 (+9.40% upside). PFE has 15 analysts with a target of $27.33 (+2.36% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.